Boulding Mark Elliott
SEC CIK 1578852 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | EVP, CLO | 108.1K | — | $24.68M | 68 | 2021-07-08 | 2026-08-17 |
Most active insiders at PTCT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Almstead Neil Gregory | CHIEF TECHNICAL OPS Off | — | $25.99M |
| 2 | Pauwels Eric | Chief BUSINESS Off | — | $7.48M |
| 3 | SCHMERTZLER MICHAEL | Dir | — | $6.31M |
| 4 | Boulding Mark Elliott | EVP AND CLO | — | $5.96M |
| 5 | Reeve Emma | Dir | — | $4.23M |
| 6 | Klein Matthew B. | CEO, Dir | — | $4.22M |
| 7 | Jacobson Allan Steven | Dir | — | $2.91M |
| 8 | Utter Christine Marie | SVP, CAO | — | $1.94M |
| 9 | Okey Stephanie | Dir | — | $1.46M |
| 10 | Smith Mary L. | Dir | — | $1.43M |
Transactions 68
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-19 17:20 | 2026-08-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $25.69 | +2,813 | 108.1K | +3% | +$72.3K |
| DMT | 2026-08-19 17:20 | 2026-08-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $72.57 | -2,813 | 105.3K | -3% | -$204.1K |
| DMT | 2026-07-08 17:20 | 2026-07-06 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $43.36 | +5,079 | 108.1K | +5% | +$220.2K |
| DMT | 2026-07-08 17:20 | 2026-07-06 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $85.08 | -5,079 | 105.3K | -5% | -$432.1K |
| DMT | 2026-06-22 17:20 | 2026-06-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $46.54 | +10.5K | 107.3K | +11% | +$489.7K |
| DMT | 2026-06-22 17:20 | 2026-06-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $78.65 | -10.5K | 105.3K | -9% | -$822.9K |
| DT | 2026-05-19 17:20 | 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $25.69 | +2,812 | 108.0K | +3% | +$72.2K |
| DMT | 2026-05-19 17:20 | 2026-05-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $72.18 | -2,812 | 105.2K | -3% | -$203.0K |
| DMT | 2026-05-12 17:20 | 2026-05-08 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $46.54 | +3,540 | 106.0K | +3% | +$164.8K |
| DMT | 2026-05-12 17:20 | 2026-05-08 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $78.97 | -3,540 | 105.2K | -3% | -$279.6K |
| DT | 2026-04-08 17:20 | 2026-04-06 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $39.42 | +2,265 | 107.5K | +2% | +$89.3K |
| DMT | 2026-04-08 17:20 | 2026-04-06 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $69.45 | -2,265 | 105.2K | -2% | -$157.3K |
| M | 2026-02-23 | 2026-02-19 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $69.48 | -3,019 | 107.6K | -3% | -$209.8K |
| DM | 2026-02-19 | 2026-02-17+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $69.33 | -5,894 | 111.3K | -5% | -$408.6K |
| D | 2026-02-19 | 2026-02-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $25.69 | +2,813 | 114.1K | +3% | +$72.3K |
| M | 2026-01-12 | 2026-01-08+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $77.06 | -6,347 | 112.1K | -5% | -$489.1K |
| DM | 2026-01-08 | 2026-01-06+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $77.31 | -6,618 | 117.7K | -5% | -$511.6K |
| DM | 2026-01-08 | 2026-01-07 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $38.10 | +3,376 | 118.4K | +3% | +$128.6K |
| DM | 2026-01-06 | 2026-01-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $75.55 | -2,266 | 120.9K | -2% | -$171.2K |
| D | 2026-01-06 | 2026-01-02 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | A - Grant | $0.00 | +17.0K | 120.9K | +16% | $0 |
| D | 2026-01-06 | 2026-01-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $39.42 | +2,266 | 123.2K | +2% | +$89.3K |
| DM | 2025-11-19 | 2025-11-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $75.99 | -2,812 | 103.9K | -3% | -$213.7K |
| D | 2025-11-19 | 2025-11-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $25.69 | +2,812 | 106.7K | +3% | +$72.2K |
| DM | 2025-10-09 | 2025-10-07 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $63.43 | -3,375 | 104.2K | -3% | -$214.1K |
| D | 2025-10-09 | 2025-10-07 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $38.10 | +3,375 | 107.3K | +3% | +$128.6K |
| DM | 2025-10-07 | 2025-10-03+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $39.42 | +24.9K | 122.0K | +26% | +$982.4K |
| DM | 2025-10-07 | 2025-10-03+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $65.75 | -24.9K | 103.9K | -19% | -$1.64M |
| DM | 2025-09-15 | 2025-09-11+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $61.18 | -47.2K | 103.9K | -31% | -$2.89M |
| DM | 2025-09-15 | 2025-09-11+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $38.10 | +47.2K | 104.8K | +82% | +$1.80M |
| D | 2025-08-19 | 2025-08-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $48.58 | -2,813 | 103.9K | -3% | -$136.7K |
| D | 2025-08-19 | 2025-08-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $25.69 | +2,813 | 106.7K | +3% | +$72.3K |
| DM | 2025-05-19 | 2025-05-15+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $46.13 | -2,812 | 103.9K | -3% | -$129.7K |
| DM | 2025-05-19 | 2025-05-15+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $25.69 | +2,812 | 105.8K | +3% | +$72.2K |
| DM | 2025-03-14 | 2025-03-12 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $33.02 | +15.5K | 106.3K | +17% | +$512.5K |
| DM | 2025-03-14 | 2025-03-12 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $53.30 | -15.5K | 103.9K | -13% | -$827.2K |
| DM | 2025-03-12 | 2025-03-10+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $53.08 | -75.4K | 103.9K | -42% | -$4.00M |
| DM | 2025-03-12 | 2025-03-10+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $31.93 | +75.4K | 115.2K | +190% | +$2.41M |
| M | 2025-02-21 | 2025-02-19+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $50.11 | -2,947 | 103.9K | -3% | -$147.7K |
| M | 2025-01-10 | 2025-01-07+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $44.87 | -3,541 | 106.8K | -3% | -$158.9K |
| D | 2025-01-07 | 2025-01-03 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | A - Grant | $0.00 | +18.0K | 110.4K | +19% | $0 |
| DM | 2024-12-04 | 2024-12-02+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $52.37 | -95.9K | 92.5K | -51% | -$5.02M |
| DM | 2024-12-04 | 2024-12-02+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $49.07 | +95.9K | 176.0K | +120% | +$4.71M |
| DM | 2024-02-16 | 2024-02-15 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | A - Grant | $0.00 | +21.2K | 92.4K | +30% | $0 |
| 2024-02-01 | 2024-01-30 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $27.25 | -794 | 71.2K | -1% | -$21.6K | |
| M | 2024-01-10 | 2024-01-08+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $28.85 | -3,395 | 72.0K | -5% | -$97.9K |
| DM | 2023-04-19 | 2023-04-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $30.86 | +61.9K | 134.0K | +86% | +$1.91M |
| DM | 2023-04-19 | 2023-04-17 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $51.42 | -61.9K | 75.4K | -45% | -$3.18M |
| 2023-02-02 | 2023-01-31 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $45.63 | -812 | 75.4K | -1% | -$37.1K | |
| M | 2023-01-12 | 2023-01-10+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $43.58 | -1,085 | 76.2K | -1% | -$47.3K |
| 2023-01-11 | 2023-01-09 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale | $41.66 | -835 | 77.3K | -1% | -$34.8K | |
| D | 2023-01-09 | 2023-01-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | A - Grant | $0.00 | +17.0K | 78.1K | +28% | $0 |
| DM | 2022-10-19 | 2022-10-17+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $30.86 | +6,901 | 61.1K | +13% | +$213.0K |
| DM | 2022-10-19 | 2022-10-17+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $55.00 | -6,901 | 61.1K | -10% | -$379.6K |
| DM | 2022-09-22 | 2022-09-20 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $55.00 | -1,176 | 61.1K | -2% | -$64.7K |
| DM | 2022-09-22 | 2022-09-20 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $30.86 | +1,176 | 61.4K | +2% | +$36.3K |
| D | 2022-04-15 | 2022-04-13 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $11.23 | +2,276 | 63.4K | +4% | +$25.6K |
| D | 2022-04-15 | 2022-04-13 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $45.17 | -2,276 | 61.1K | -4% | -$102.8K |
| D | 2022-04-07 | 2022-04-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | M - OptEx | $11.23 | +5 | 61.1K | +0.0% | +$56.15 |
| D | 2022-04-07 | 2022-04-05 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP AND CLO | S - Sale+OE | $45.00 | -5 | 61.1K | -0.0% | -$225 |
| DM | 2022-02-11 | 2022-02-10 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $45.03 | -17.9K | 61.1K | -23% | -$807.6K |
| DM | 2022-02-11 | 2022-02-10 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | M - OptEx | $17.15 | +17.9K | 63.4K | +39% | +$307.5K |
| 2022-02-03 | 2022-02-01 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | S - Sale | $40.00 | -779 | 61.1K | -1% | -$31.2K | |
| D | 2022-01-11 | 2022-01-07 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | S - Sale | $38.53 | -885 | 47.5K | -2% | -$34.1K |
| D | 2022-01-11 | 2022-01-07 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | A - Grant | $0.00 | +14.4K | 61.9K | +30% | $0 |
| D | 2021-09-03 | 2021-09-02 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | M - OptEx | $18.01 | +3,363 | 51.7K | +7% | +$60.6K |
| D | 2021-09-03 | 2021-09-02 | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $45.01 | -3,363 | 48.4K | -7% | -$151.4K |
| DM | 2021-07-12 | 2021-07-08+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $45.19 | -9,234 | 48.4K | -16% | -$417.3K |
| DM | 2021-07-12 | 2021-07-08+ | PTCT | PTC THERAPEUTICS, INC. | Boulding Mark Elliott | EVP, CLO | M - OptEx | $16.54 | +9,234 | 48.8K | +23% | +$152.7K |
Purchase Sale Sale after option exercise All abbreviations